drugset / Trial / NCT02915796

Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty

NCT02915796 ↗

Phase 1 Unknown 345 enrolled Shanghai 10th People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The main aim of the present study was to evaluate the therapeutic potential and safety of transarterial infusion of granulocyte colony stimulating factor (G-CSF) mobilized cluster of differentiation (CD) 133(+) cells when combined with percutaneous transluminal angioplasty (PTA) in treatment of below the knee (BTK) peripheral arterial disease (PAD) in diabetic patients.

Timeline

Start
2016-09
Primary completion
2017-04
Completion
2018-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CD133(+) cells Cell therapy 50 ml Other
Subject recombinant human G-CSF Unknown 150 iu Intramuscular